Real‐World Associations of Renin–Angiotensin–Aldosterone System Inhibitor Dose Hyperkalemia and Adverse Clinical Outcomes in a Cohort of Patients With New‐Onset Chronic Kidney Disease or Heart Failure in the United Kingdom

摘要

Dosing of renin–angiotensin–aldosterone system inhibitors ( i) may be modified to manage associated hyperkalemia risk; however, this approach could adversely affect cardiorenal outcomes. This study investigated real‐world associations of i dose, hyperkalemia, and adverse clinical outcomes in a large cohort of cardiorenal patients.